It depends on how you define "short-term". The Phase 3 results from the eprat lupus trials will blow this stock up. It's the only therapy to show benefit in Phase 2 (BENLYSTA did not). It will represent a major upgrade to the BENLYSTA dud... Rheumatologists already love B-cell depletion therapy. The anti-CD22 approach offers a deviation from the anti-CD20 approach.
EULAR is in June & ACR is in November... I would not be surprised to start seeing some of the data presented at these meetings... If you are not leveraged in, you may miss the window to really capitalize.
$10 is conservative for this stock over the next 12 months... $22-$25 is quite possible
News 
Market Data 
Discover 
AI
